Clinical Trial Update: Effect of Melatonin on Cardiometabolic Risk- FULL [Phase 3]

View source ↗

Summary

An update on a Phase 3 clinical trial investigating melatonin's effect on cardiometabolic risk in obesity and prediabetes; current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Prediabetes

Drugs mentioned

• Melatonin (melatonin)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Obesity, Prediabetic State | Phase 3 | Status: UNKNOWN